Amneal Pharmaceuticals, Inc. is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.
Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A. In 2018, the acquisition of Impax Laboratories expanded its specialty footprint and R&D capabilities, leading to the creation of Amneal Specialty. The company maintains research centers in New Jersey and India, where teams focus on formulation science, bioequivalence studies and advanced drug delivery technologies.
Amneal’s manufacturing network comprises facilities in the United States, Ireland and India, enabling the company to supply markets across North America, Europe and select emerging regions. Its vertically integrated model extends from active pharmaceutical ingredient (API) production to finished-dose manufacturing, supported by a global quality and regulatory framework. This structure allows Amneal to manage supply chain resilience and maintain cost efficiencies in a competitive generics landscape.
Leadership at Amneal is spearheaded by co-CEOs Chirag and Chintu Modgil, who bring experience in pharmaceutical operations and strategy. The executive team includes President Gregory Divis, overseeing commercial and pipeline functions, as well as a cohort of seasoned professionals in regulatory affairs, quality assurance and global manufacturing. Together, the leadership team aims to drive sustainable growth by expanding product offerings and enhancing patient access to affordable medicines.
AI Generated. May Contain Errors.
Free AMRX Stock Alerts